Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
2024 · Nature Medicine · 69 citations
https://doi.org/10.1038/s41591-024-03086-4
J
Joann Hsu
City of Hope(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
178
Papers
2.0K
Citations
20
h-index
32
i10-index
Joann Hsu is an academic researcher from City of Hope. The author has contributed to research in topics: Renal cell carcinoma treatment & Cancer Genomics and Diagnostics & Cancer Immunotherapy and Biomarkers. The author has an h-index of 20, co-authored 152 publications.
ORCID: 0000-0001-9452-5980Papers by this author
worksUltrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
2023 · JCO Precision Oncology · 22 citations
https://doi.org/10.1200/po.22.00543
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy
2024 · Frontiers in Immunology · 16 citations
https://doi.org/10.3389/fimmu.2023.1274781
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion
2025 · Cancer Medicine · 2 citations
https://doi.org/10.1002/cam4.70696
Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer
2018 · European Urology · 0 citations
https://doi.org/10.1016/j.eururo.2018.04.024
1699P Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
2024 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2024.08.1792
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat